Plasma phospholipid fatty acids, dietary fatty acids and prostate cancer risk

被引:40
|
作者
Bassett, Julie K. [1 ]
Severi, Gianluca [1 ,2 ]
Hodge, Allison M. [1 ]
MacInnis, Robert J. [1 ,2 ]
Gibson, Robert A. [3 ]
Hopper, John L. [2 ]
English, Dallas R. [1 ,2 ]
Giles, Graham G. [1 ,2 ,4 ]
机构
[1] Canc Council Victoria, Canc Epidemiol Ctr, Carlton, Vic 3053, Australia
[2] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne Sch Populat & Global Hlth, Carlton, Vic 3053, Australia
[3] Univ Adelaide, FOODplus Res Ctr, Glen Osmond, SA, Australia
[4] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia
基金
英国医学研究理事会;
关键词
fatty acids; prostate cancer; cohort study; ALPHA-LINOLENIC ACID; SATURATED FAT; DAIRY PRODUCT; OLIVE OIL; PREVENTION; DISEASE; COHORT; BLOOD; CONSUMPTION; MECHANISMS;
D O I
10.1002/ijc.28203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Animal and experimental studies have demonstrated that long-chain n-3 fatty acids inhibit the development of prostate cancer, whereas n-6 fatty acids might promote it. We performed a case-cohort analysis within the Melbourne Collaborative Cohort Study using a random sample of 1,717 men and 464 prostate cancer cases to investigate associations between fatty acids assessed in plasma phospholipids (PPLs) or diet (estimated using a 121-item food frequency questionnaire) and prostate cancer risk. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox regression. Prostate cancer risk was positively associated with %PPL saturated fatty acids (SFAs); HR [95% CI] = 1.51 [1.06, 2.16] (Q5 vs. Q1, fifth vs. first quintile); p-trend = 0.003. HRs (Q5 to Q2 vs. Q1) were significantly elevated for %PPL palmitic acid. %PPL oleic acid was inversely associated with risk, HR = 0.62 [0.43, 0.91] (Q5 vs. Q1); p-trend = 0.04. No statistically significant linear trends were observed for dietary intakes. The HRs were elevated for moderate intakes of linoleic acid (Q2 and Q3 vs. Q1, 1.58 [1.10, 2.28] and 1.70 [1.18, 2.46], respectively), but the increase was not significant for higher intakes (Q4 and Q5). No association varied significantly by tumour aggressiveness (all p-homogeneity > 0.1). Prostate cancer risk was positively associated with %PPL SFA, largely attributable to palmitic acid and inversely associated with %PPL monounsaturated fatty acids, largely attributable to oleic acid. Higher risks were also observed for dietary n-6 polyunsaturated fats, primarily linoleic acid. What's new? Animal and experimental studies have demonstrated that long'chain n'3 fatty acids inhibit the development of prostate cancer, whereas n'6 fatty acids might promote it. Whether similar associations exist for humans, however, has been unclear. This analysis of data from the Melbourne Collaborative Cohort Study suggests that dietary intake of the n'6 linoleic acid and percentage of saturated fatty acid in plasma phospholipids are positively associated with prostate cancer risk. In addition, a higher percentage of n'9 oleic acid in plasma phospholipids was found to possibly reduce prostate cancer risk.
引用
收藏
页码:1882 / 1891
页数:10
相关论文
共 50 条
  • [1] Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial
    Brasky, Theodore M.
    Darke, Amy K.
    Song, Xiaoling
    Tangen, Catherine M.
    Goodman, Phyllis J.
    Thompson, Ian M.
    Meyskens, Frank L., Jr.
    Goodman, Gary E.
    Minasian, Lori M.
    Parnes, Howard L.
    Klein, Eric A.
    Kristal, Alan R.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (15) : 1132 - 1141
  • [2] Plasma Phospholipid Fatty Acids and Prostate Cancer Risk (SELECT Trial)
    Ruebben, H.
    [J]. UROLOGE, 2014, 53 (09): : 1362 - 1363
  • [3] Plasma phospholipids fatty acids, dietary fatty acids, and breast cancer risk
    Bassett, Julie K.
    Hodge, Allison M.
    English, Dallas R.
    MacInnis, Robert J.
    Giles, Graham G.
    [J]. CANCER CAUSES & CONTROL, 2016, 27 (06) : 759 - 773
  • [4] Plasma phospholipids fatty acids, dietary fatty acids, and breast cancer risk
    Julie K. Bassett
    Allison M. Hodge
    Dallas R. English
    Robert J. MacInnis
    Graham G. Giles
    [J]. Cancer Causes & Control, 2016, 27 : 759 - 773
  • [5] Re: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial
    Chow, Ken
    Murphy, Declan G.
    [J]. EUROPEAN UROLOGY, 2013, 64 (06) : 1015 - 1016
  • [6] RE: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial
    El-Bayoumy, Karam
    Thompson, Henry
    Manni, Andrea
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (04)
  • [7] Re: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial
    Sosnowski, Roman
    Zawistowski, Jerzy
    [J]. EUROPEAN UROLOGY, 2014, 65 (05) : 1012 - 1012
  • [8] RE: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial Response
    Brasky, Theodore M.
    Thompson, Ian M.
    King, Irena B.
    Kristal, Alan R.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (04)
  • [9] Re: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial Editorial Comment
    Taneja, Samir S.
    [J]. JOURNAL OF UROLOGY, 2014, 191 (03): : 658 - 658
  • [10] THE ASSOCIATION OF PLASMA FATTY ACIDS WITH PROSTATE CANCER RISK IN NIGERIANS
    Ukoli, Flora A.
    Akumabor, Philip N.
    Oguike, Temple C.
    Dent, Lemuel L.
    Beech, Derrick
    Osime, Usifo
    [J]. ETHNICITY & DISEASE, 2009, 19 (04) : 454 - 461